La Trobe
- No file added yet -

Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS

Download (2.05 MB)
journal contribution
posted on 2022-05-04, 04:58 authored by M Machcińska, M Kierasińska, M Michniowska, M Maruszewska-Cheruiyot, L Szewczak, R Rola, A Karlińska, Michael StearMichael Stear, K Donskow-łysoniewska
Altered regulatory T cell (Treg) function could contribute to MS. The expression of activating and inhibitory receptors influences the activity of Tregs. Our aim was to investigate T cell phenotypes in relapsing–remitting MS (RRMS) patients at an early phase of the disease. We examined the influence of demographic parameters on the distribution of CD4+ and CD8+ T cell subclasses by generalized linear modeling. We also studied the expression of the following markers—CTLA-4, GITR, PD-1, FoxP3, Helios, CD28, CD62L, CD103—on T cell subsets from peripheral blood with a 14-color flow cytometry panel. We used an antibody array to define the profiles of 34 Th1/Th2/Th17 cytokines in the serum. Expression of PD-1 and GITR on CD4+ and CD8+ Tregs was decreased in RRMS patients. The proinflammatory factors IFN-γ, IL-17, IL-17F, TGFβ-1, TGFβ-3, IL-1SRII, IL-12 p40, sgp130, IL-6sR were significantly increased in RRMS patients. Therefore, a deficiency of PD-1 and GITR immune checkpoints on CD4+ and CD8+ Tregs is a feature of RRMS and might underlie impaired T cell control.

Funding

This work was supported by grants from the TEAM TECH/2017-4/22 project carried out within the TEAM TECH programme of the Foundation for Polish Science, co-financed by the European Union under the European Regional Development Fund.

History

Publication Date

2022-03-01

Journal

International Journal of Molecular Sciences

Volume

23

Issue

6

Article Number

ARTN 3185

Pagination

12p.

Publisher

MDPI

ISSN

1661-6596

Rights Statement

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)